Delta-Fly Pharma, Inc. Statistics
Want to see JP:4598 full AI Analyst Report?
Delta-Fly Pharma, Inc. (4598) Stock Statistics & Valuation Metrics
Total Valuation
Delta-Fly Pharma, Inc. has a market cap or net worth of JPY 1.25B. The enterprise value is JPY 1.72B.
- Market Cap
- JPY 1.25B
- Enterprise Value
- JPY 1.72B
Share Statistics
Delta-Fly Pharma, Inc. has 20,195,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 20,195,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Delta-Fly Pharma, Inc.’s return on equity (ROE) is -47.85 and return on invested capital (ROIC) is -4723.63%.
- Return on Equity (ROE)
- -47.85
- Return on Assets (ROA)
- -6.59
- Return on Invested Capital (ROIC)
- -4723.63%
- Return on Capital Employed (ROCE)
- -47.24
- Revenue Per Employee
- 0
- Profits Per Employee
- -135.50M
- Employee Count
- 12
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Delta-Fly Pharma, Inc. is -0.45. Delta-Fly Pharma, Inc.’s PEG ratio is -0.02.
- PE Ratio
- -0.45
- PS Ratio
- 0.00
- PB Ratio
- -4.35
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Delta-Fly Pharma, Inc. had revenue of 0 and earned -1.63B in profits. Earnings per share was -140.45.
- Revenue
- 0
- Gross Profit
- -1.44M
- Operating Income
- -1.61B
- Pretax Income
- -1.62B
- Net Income
- -1.63B
- EBITDA
- -1.60B
- Earnings Per Share (EPS)
- -140.45
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Delta-Fly Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -193.90%
Stock Price Statistics
- Beta
- 0.46
- 52-Week Price Change
- -87.45%
- 50-Day Moving Average
- 93.28
- 200-Day Moving Average
- 147.47
- Relative Strength Index (RSI)
- 31.32
- Average Volume (3m)
- 1.42M
Important Dates
Delta-Fly Pharma, Inc. upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Feb 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Delta-Fly Pharma, Inc. as a current ratio of 0.98, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.98
- Quick Ratio
- 0.98
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.09
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Delta-Fly Pharma, Inc. has paid 2.50M in taxes.
- Income Tax
- 2.50M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Delta-Fly Pharma, Inc. EV to EBITDA ratio is -0.48, with an EV/FCF ratio of 0.00.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.48
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Delta-Fly Pharma, Inc. has JPY 83.33M in cash and marketable securities with JPY 0.00 in debt, giving a net cash position of JPY 83.33M billion.
- Cash & Marketable Securities
- JPY 83.33M
- Total Debt
- JPY 0.00
- Net Cash
- JPY 83.33M
- Net Cash Per Share
- JPY 4.13
- Tangible Book Value Per Share
- -JPY 14.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Delta-Fly Pharma, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 20.94%
Scores
- Smart Score
- ―
- AI Score
- 42

